Article
A Novel Full-Length Recombinant Human Complement Factor H (CFH; GEM103) for the Treatment of Age-Related Macular Degeneration Shows Similar In Vitro Functional Activity to Native CFH.
Current eye research - 1 Jul 2022
Biggs Robyn M, Makou Elisavet, Lauder Scott, Herbert Andrew P, Barlow Paul N, Katti Suresh K
Abstract excerpt
PURPOSE: GEM103 is a recombinantly produced full-length version of the human complement factor H (CFH) under clinical investigation for treatment of age-related macular degeneration (AMD) in individuals carrying an AMD risk-associated genetic variant of CFH. This study aimed to investigate the complement pathway-related functions of GEM103 in comparison with those of native human CFH. METHODS: Key biological...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.